Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q3 2026 Earnings Presentation
10 slides from Avita Medical's earnings presentation, Nov 6, 2026
Slide 1: Third Quarter 2026 Financial and Business Update
rsonal use only Third Quarter 2026 Financial and Business Update November 5, 2026
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and un
Slide 3: Strong third quarter revenue and cash use of $0.6 million, raising 2026 guidance
AVITA delivered strong third quarter revenue and cash use of $0.6 million, supporting a further increase to 2026 full year revenue guidance Revenue Cash use rsonal use only in USD millions in USD millions Q3 Q4 Q1 Q2 Q3 2025 2025 2026 2026 2026 $6.2 $5.1 $9.9 $3.2 $0.6 $17.1 $17.6 $19.3 $21.7 $26.1
Slide 4: RECELL continued to drive robust growth, with Cohealyx growing 21% sequentially
RECELL continued to drive robust growth, with Cohealyx growing 21% sequentially Portfolio quarter-over-quarter Total U.S. RECELL volume by quarter rsonal use only in USD millions in units +20.9% Q2 2026 Q3 2026 +11.3% US RECELL® $18.5 $22.4 ~20% +12% +1.8% Cohealyx ® $1.7 $2.1 ~21% PermeaDerm ® $0.6
Slide 5: PermeaDerm demonstrates comparable clinical outcomes to allograft
PermeaDerm demonstrates comparable clinical outcomes to allograft for wound temporization while reducing product costs and preparation time Multi-center randomized controlled study (n = 40; 11 U.S. burn centers) rsonal use only 70% Lower Product Cost 95.7% Mean Reduction in Comparable graft take and
Slide 6: Three complementary technologies supporting clinicians across acute wound care
Three complementary technologies that support clinicians across the continuum of acute wound care Regional conferences highlight rsonal use only growing portfolio evidence 26x presentations accepted across the 2026 American Burn Association regional conference program Includes: 1 PREPARE 2 REBUILD 3
Slide 7: Q3 revenue up 53% year-on-year; gross margin increased to 84%
Q3 revenue up 53% year-on-year and 20% sequentially, with higher sales compensation lifting OpEx, and gross margin increased to 84% Key figures Q3 Q3 Change vs Q2 Change vs rsonal use only in USD millions 2026 2025 prior year 2026 Q2 2026 Revenue $26.1 $17.1 +53% $21.7 +20% Gross profit margin 84% 8
Slide 8: Raising 2026 revenue guidance; affirming cash flow breakeven in Q4
Raising 2026 revenue guidance and restoring attractive growth profile; affirming cash flow breakeven in the fourth quarter Revenue ~28% rsonal use only Updated full year 2026 guidance in USD millions Revenue CAGR Forecast from 2022–2026E* +30%* Revenue expected +11% +28% to grow: +46% $92M to $94M +
Slide 9: Summary
Summary rsonal use only Continued Raised FY 2026 PermeaDerm On track to business revenue guidance demonstrates achieve cash flow momentum in Q3, for a second comparable breakeven in Q4 with 53% year on sequential time clinical outcomes year and 20% to allograft while sequential revenue reducing prod
Slide 10: rsonal use only
rsonal use only